nerofe

Nerofe is a synthetic 14-amino acid peptide derived from the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It is designed as a first-in-class cancer suppressive agent and acts primarily by binding to the T1/ST2 receptor (also known as IL1RL1), which is overexpressed in certain cancer cells. Upon binding, Nerofe activates caspase 8 and Bcl-2 mediated apoptotic pathways and triggers p38 MAPK and JNK signaling cascades in tumor cells. This results in selective induction of apoptosis in proliferating malignant cells while sparing non-proliferating cells. Additionally, Nerofe inhibits angiogenesis by downregulating VEGFA and VEGFR1 expression and modulates immune responses through increased interleukin-10 production. The drug is administered intravenously as an infusion. It has been investigated for use in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), advanced solid tumors including pancreatic cancer, triple-negative breast cancer, metastatic ovarian cancer, renal cell carcinoma, metastatic colorectal carcinoma, and Alzheimer’s disease[1][3][4][5][7].

Brand names

Nerofe

Other names

tumor-cells apoptosis factortumor-cells apoptosis factor hormone-peptideTCApFWWTFFLPSTLWERK